FDA Revises Guidance On RRAs With Updated Q&As

 
• By Brian Bossetta

The FDA has revised draft guidance issued in 2022 on how the agency plans to continue using remote technology to assess regulated facilities. The FDA established remote assessments in early 2021 to keep up its regulatory obligations during the COVID-19 pandemic.

Remote Access
• Source: Shutterstock

During the COVID-19 pandemic, the US Food and Drug Administration expanded its use of remote regulatory assessments (RRAs), which allowed the agency to keep its eyes on facilities without investigators having to go on-site.

Based on its experience using RRAs amid the pandemic, the FDA has concluded it should keep the remote

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation